• share
• favorite_border

Houston Methodist researchers will be part of a national consortium funded by an up to $49 million award from the U.S. Government鈥檚 Advanced Research Projects Agency for Health (ARPA-H) to develop a vaccine against two of the most common and destructive strains of herpesviruses that latently infect a majority of Americans and can lead to acute infections, multiple forms of cancer, autoimmune disease and birth defects.

• share
• favorite_border

Irvine, Calif., Oct. 3, 2024 鈥� With an initial three-year, $33 million grant from the National Institute of Allergy and Infectious Diseases, the University of California, Irvine will lead a multi-institutional drive to create new vaccines as part of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness Network (ReVAMPP).

• share
• favorite_border

• share
• favorite_border

Research shows people previously vaccinated against mpox in 2022 had declining antibody responses after six to 12 months, as World Health Organization (WHO) designates the 2024 mpox outbreak a public health emergency of international concern.

• share
• favorite_border

Since May 18, 2022, cases of mpox have been spreading in the United States, including California. Since August 2024, there has been a new outbreak declared due to a significant increase in cases from the Democratic Republic of Congo and its neighboring countries in Central and East Africa. Here's everything families need to know about mpox.

• share
• favorite_border

The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the United States each year, according to the Centers for Disease Control and Prevention. New images of the virus from researchers at the University of Wisconsin鈥揗adison may hold the key to preventing or slowing RSV infections.

• share
• favorite_border

September usually marks the start of flu season, and with the ongoing threat of COVID-19, it鈥檚 crucial to be vigilant about your family鈥檚 health. The challenge, however, is being able to tell the difference between the flu, the common cold, respiratory syncytial virus (RSV) and COVID-19, since all have similar symptoms.

• share
• favorite_border

A study of more than 28,000 pregnancies from 2022 has found that the majority of pregnant people received the COVID-19 vaccine during its initial release.

• share
• favorite_border

In a new study funded by the National Institutes of Health, University of Georgia researchers found that natural immunity from previous flu infections has a significant impact on how well future influenza vaccinations work.

• share
• favorite_border

Researchers at WashU Medicine have received a $12 million grant from the National Institute of Allergy and Infectious Diseases to identify the factors that are responsible for long-lasting immunity against disease.

• share
• favorite_border

Rabies is a virus that affects the central nervous system in mammals, leading to brain inflammation. Rabies is almost always fatal once there are symptoms, but it is also 100 percent preventable with proper precautions and vaccination. Understanding the risks and taking preventative measures is essential in protecting animals, families, and communities.

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

The new study, led by researchers in the Saphire Lab at LJI, reveals the inner workings of the Ebola virus nucleocapsid. LA JOLLA, CA鈥擜t this moment, the world has few tools to combat deadly filoviruses, such as Ebola and Marburg viruses. The only approved vaccine and antibody treatments protect against just one filovirus species.

• share
• favorite_border

The LJI team uncovered important similarities between H5N1 and these common viruses, which allowed them to predict that many people already have "cross-reactive" T cells that are ready to target H5N1鈥攕hould it ever mutate to cause widespread disease in humans.

• share
• favorite_border

WashU Medicine scientists lead two large, multicenter programs to develop vaccines and antibody-based therapies for understudied viruses with pandemic potential. The programs are supported by two grants from the National Institute for Allergy and Infectious Diseases (NIAID) totaling more than $30 million a year for three years.

• share
• favorite_border

Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop "plug-and-play" vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID鈥檚 new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.

• share
• favorite_border

With flu season just around the corner and COVID-19 cases on the rise, a new nationwide survey from The Ohio State University Wexner Medical Center reveals hesitancy around vaccines this fall. The new data comes just as this year鈥檚 flu shot rolls out and following the FDA鈥檚 approval of an updated round of COVID-19 vaccines.

• share
• favorite_border

La Jolla Institute for Immunology (LJI) has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).